CEL-SCI Multikine Phase 3 data accepted by Oral Oncology journal

July 30, 2026 8:31 AM

CEL-SCI Corporation (NYSE American: CVM) announced that a manuscript based on data from its Phase 3 IT-MATTERS clinical trial evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found